JAMPRO
30.9.2021 21:32:09 CEST | Business Wire | Press release
The Jamaica Promotions Corporation (JAMPRO) will be staging Explore: Do Business Jamaica Virtual Investment Conference (DBJVIC) from November 17 – 18, 2021 to introduce local and international investors to business opportunities in the island’s growing industries.
The event will showcase emerging projects and new developments in Agribusiness, Outsourcing, Manufacturing, Energy, Tourism, and the Creative Industries through over 30 panels, interviews and discussions with government and business leaders. The investment conference aims to foster business and stakeholder relationships and will shed light on Jamaica’s COVID-19 economic recovery efforts.
The conference will be staged concurrently via two platforms; one is a virtual interactive business event portal that will facilitate a real-time engagement experience and B2B meetings, the second is a live stream event via social media that will accommodate and drive increased awareness of Jamaica’s economic progress. This format will help JAMPRO to engage attendees including current and potential investors, JAMPRO clients, private and public sector stakeholders, and diplomatic missions.
JAMPRO anticipates extensive global participation based on the planned international promotions which will ensure the leveraging of the virtual B2B meeting platform by potential investors.
New opportunity to do business
Speaking on the event, Jamaica’s Minister of Industry, Investment, and Commerce, The Honourable Audley Shaw, CD, MP., noted that the virtual investment conference has presented a new opportunity for the government to amplify the promotion of Jamaica’s business opportunities.
He explained, “This virtual conference will allow us to reach and directly engage investors across the globe who are interested in doing business with Jamaica but need further market intelligence and guidance on the potential that is available in the island’s sectors. From our perspective, it is the right time to host this global event, as persons are seeking new ventures as the world slowly returns to normality .”
Diane Edwards, President of JAMPRO, echoed the Minister’s statements, and expressed confidence in the conference’s ability to deliver results for Jamaica and attendees, she said, “The format of the conference is powerful, because it presents an excellent opportunity for global business leaders to get valuable insight on Jamaican investment opportunities, engage their colleagues in various industries, and explore bankable projects, all in the location of their choice. We believe that this conference will lead to the development of lucrative partnerships and financial opportunities for local and international investors. ”
Persons can register for the event at explore.dobusinessjamaica.com
ABOUT THE EXPLORE: DO BUSINESS JAMAICA VIRTUAL INVESTMENT CONFERENCE (DBJVIC)
Explore: Do Business Jamaica Virtual Investment Conference is a 2-day event that will highlight investment and other business opportunities in Jamaica. The event, hosted by Jamaica’s investment and export promotion agency, JAMPRO, will provide a platform for attendees to learn more about Jamaican investment opportunities, see lucrative projects, and build business relationships.
Explore Do Business Jamaica Virtual Investment Conference is sponsored by the Foundations for Competitiveness and Growth Project (FCGP), National Commercial Bank (NCB), Mystique Integrated, and M-One Productions
For more information on the conference, please visit https://explore.dobusinessjamaica.com/ .
Follow JAMPRO on:
Twitter
Facebook
Instagram
LinkedIn
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005861/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom